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[57] ' ABSTRACT 
An inactivated viral vaccine for protecting horses 
against disease caused by equine rhinopneumonitis virus 
is prepared by propagating an equine rhinopneumonitis 
virus in a susceptible, cloned, diploid equine cell line, 
harvesting the resulting virus in a serum-free medium, 
inactivating the virus and neutralizing the inactivating 
agent, concentrating the virus, and adding an immuno 
logical adjuvant thereto. A vaccination program to 
protect horses against the equine rhinopneumonitis 
virus is also disclosed. 
9 Claims, N0 Drawings 
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INACTIVATED EQUINE RHINOPNEUMONITIS 
VIRUS VACCINE AND USE THEREOF 
This invention relates to the development of a pre 
ventive immunization method for protecting pregnant - 
mares against the abortigenic effect of equine rhinop 
neumonitis virus (equine herpesvirus I) infection and of 
protecting young horses against disease caused by their 
infection by the same virus and to the process of prepa 
ration of the potent vaccine. 
The equine rhinopneumonitis virus (ERV), a typical 
member of the Herpesvirus group, infects the respira 
tory mucosa and subjacent or associated lymphoreticu 
lar organs leading to development of a cell-associated 
viremic state which may lead to abortigenic infection of 
the fetus in pregnant mares. The economic losses conse 
quent to disease produced by this infection in young 
horses result from inability or impaired ability to per 
form in competition. The economic losses resulting 
from infection of pregnant mares are due to abortion. 
The disease occurs in enzootic form but may occur in 
epizootic form resulting in fetal or neonatal loss of 
greater than 50 percent of expected foal crop produc 
tion in individual bands of mares. 
Hitherto, it has not been possible to prevent such loss 
without risk of vaccine induced abortic infection in 
which living virus vaccines are administered either 
intranasally or parenterally. Infectious (living 
attenuated) vaccines may not be used except in early or 
mid-gestation, these periods being the least critical dur 
ing which protection is required. 1 
It is known that certain properly constituted, chemi 
cally inactivated, non-infectious viral vaccines will pro 
tect mammals against disease caused by speci?c viruses. 
There is, however, no teaching in the art, or no example 
in the scienti?c literature, that an inactivated viral vac 
cine will protect mares against abortigenic infection by 
equine rhinopneumonitis herpesvirus. 
The present invention provides an injectable vaccina 
tion program, timed to coincide with the most suscepti 
ble period of gestation of the equine fetus, as well as an 
immunogenically potent vaccine for immunizing horses 
against equine viral rhinopneumonitis and a process for 
preparing the vaccine wherein an antigenically typical 
and virulent equine rhinopneumonitis virus, propagated 
in a physiologically homogeneous cell culture derived 
as the recent progeny of a single cell cloned from a cell 
culture derived from the skin of a normal equine fetus, 
is chemically inactivated, concentrated by ultra?ltra 
tion and mixed for enhancement of immunogenic po 
tency for injection with an oil based immunological 
adjuvant. 
More particularly, the invention provides an intra 
muscular vaccination protocol for protection of preg 
nant mares against abortion caused by equine rhinop 
neumonitis viral infection which consists in vaccinating 
pregnant mares by injection in the 5th month of preg 
nancy, in the 7th month and in the 9th month of preg 
nancy, and of immunizing non-pregnant yearlings by a 
series of two injections in September and an annual 
single injection vaccination until such female yearlings 
reach breeding age and become pregnant with a vaccine 
prepared by: 
(A) Preparing from the dermis of a normal equine 
fetus, removed aseptically from a pregnant normal 
mare, a cell culture which by karyotypic analysis is 
shown to be a diploid male or female idiogram without 
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any abnormal chromosome markers and containing the 
normal modal chromosome number for Equus caballus 
(64), 
(B) Preparing from this cell culture, single cell cloned 
diploid cell lines which by karyotypic analysis reveal a 
stable emploidy and showing, by virus culture, electron 
microscopy, bacteriological culture and uridine-uracil 
ratio, that such cell lines are free of adventitious viruses, 
bacterial or mycoplasma, 
(C) Determining by inoculation of horses and prepa 
ration of antiserums in rabbits against the cell culture 
that the cell culture contains no equine red blood cell 
antigens, - 
(D) Inoculating such cell lines with a multiplicity of 
infections shown to produce maximum infectious virus 
particle yields of a stable macroplaque strain of an anti 
genically typical equine rhinopneumonitis virus and 
causing the virus to be released into a serum-free me 
dium, and 
(E) Harvesting such serum-free virus containing ma 
terial from infected cell culture, removing cell culture 
debris by centrifugation, chemically inactivating infec 
tivity of the virus with such chemicals as formalin, 
beta-propiolactone or acetylethylenimine, neutralizing 
any residual chemical, concentrating the virus by ultra 
?ltration, adding a stabilizing agent, adding a preserva 
tive, ascertaining that no residual infectious virus is 
present and mixing the virus with an oil based immuno 
logic adjuvant. Said virus before addition of adjuvant 
must meet the following criteria for inactivation and 
integrity of structure: 
(a) Virus is pelleted from a 100 ml sample of the 
completely mixed but unconcentrated inactivated virus 
base pool by centrifugation at 25,000 rpm for 1 hour. 
The pellet is resuspended in a few ml of serum-free 
balanced salt solution and two con?uent monolayers of 
susceptible cell cultures are inoculated, each with half 
of the concentrated inactivated virus. If no viral cyto 
pathic effect occurs after an incubation period of 7 days, 
each inoculated culture is harvested and transferred to a 
second set of two cell cultures. If no viral cytopathic 
effect occurs in these cultures after 7 days of incubation 
the virus is judged to be non-infectious. 
(b) A virus pellet from the concentrated inactivated 
virus base pool is examined by ultra thin section elec 
tron microscopy to determine whether the inactivated 
virus particles are enveloped. Because potency of vac 
cine requires enveloped virions, the majority of the 
virions must be so constituted. 
The inactivated virus must meet the following crite 
ria for immunogenic potency: 
The vaccine virus without adjuvant is diluted so as to 
decrease, in serial fashion, the number of inactivated 
virions in the suspension. The dilutions are extended to 
produce complete extinction of protective effect. A 
portion of each diluted virus suspension is mixed and 
emulsi?ed with an equal amount of oil based adjuvant. 
Four Syrian hamsters (Cricetus auratus) are injected 
intramuscularly with 0.2 ml of each dilution of adju 
vanted virus dilution. At the same time, four hamsters 
are mock vaccinated using a 0.2 ml intramuscular injec 
tion composed of equal amounts of emulsi?ed diluent 
and adjuvant. Three weeks later, the hamsters are all 
challenged by intraperitoneal injection of at least 1 
million hamster median lethal doses of hamster virulent 
virus. The hamsters are individually housed for the 
purposes of the test and are observed for 7 days follow 
ing challenge inoculation. The vaccine must protect 
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hamsters vaccinated with a 1:1500 dilution of the base 
vaccine virus suspension. The mock vaccinated ham 
sters must all die within 7 days, and a titration of the 
challenge virus in unvaccinated or mock vaccinated 
hamsters must show that the challenge virus contained 
at least 1 million hamster median lethal doses. The po 
tency titration endpoint is the dilution of adjuvanted 
vaccine which protects 50 percent of vaccinated ham 
sters. 
The invention further provides a process for manu 
facture of a vaccine characterized by the aforemen 
tioned'protocols and the vaccine itself as a method for 
protecting horses against disease caused by the equine 
rhinopneumonitis virus. 
As the virus, antigenically typical equine rhinop 
neumonitis virus, the A-l83 strain, is used. The A-l83 
strain is immunogenically the same as strains of equine 
rhinopneumonitis virus recovered from diseased horses 
in several countries of the world, speci?cally Germany, 
Sweden, Switzerland, France, Great Britain, Ireland, 
Japan, Australia, South Africa, Argentina, Brazil and 
the United States. The virus may be recovered by inoc 
ulation of susceptible cell cultures, from the nasophar 
ynx and/or blood of horses with respiratory disease, 
from the nasopharynx and/or blood of infected preg 
nant mares and from the organs of fetuses aborted by 
infected mares. , 
Although the virus may be cultured by multiplication 
in cell cultures derived from organs of many mamma 
lian species, for the purposes of this invention, the virus 
is cultured from the lung tissue of an infected aborted 
fetus by inoculation of a cloned, diploid cell culture 
prepared from a cell culture derived from the dermis of 
a normal equine fetus. 
The parent cell line is derived from the normal der 
mal and subcutaneous connective tissues of a normal 10 
to ll-month-old equine fetus. Monolayer cultures are 
prepared from the excised and trypsin dispersed fetal 
connective tissue; cells from early 5th to 7th passage are 
stored at —90° Centigrade. To obtain a physiologically 
homogeneous cell population in culture as the progeny 
of a single cell, cloned lines of cells are initiated from 
the early subculture generations by single cell isolation 
techniques. The growth characteristics of cloned cell 
lines are determined by such techniques as plaquing 
efficiency, generation time and cell viability. 
Karyotypic analysis of vinblastine treated cloned cell 
lines at the passage level selected for production of 
vaccine virus reveal diploid male or female idiograms 
without demonstrable chromosome markers. The cell 
lines are shown to be free of mycoplasma and adventi 
tious viruses. Such cell lines have been shown to be 
capable of propagating all strains of equine rhinop 
neumonitis virus, equine cytomegalovirus, equine coital 
exanthema virus, Herpes simplex virus, infectious bo 
vine rhinotracheitis virus, Venezuelan equine encepha 
lomyelitis virus, equine adenovirus, and equine arteritis 
virus. The cell lines can be shown to be free of equine 
infectious anemia virus by inoculation of susceptible 
horses. 
When rabbits are immunized with the cell lines, they 
produce no antibodies reactive against known equine 
red blood cell antigens. Inoculation of normal horses 
with the cell lines produces no adverse effect. 
For virus vaccine production, cell cultures are pre 
pared as con?uent monolayers in glass or plastic roller 
bottles. The cells are grown in medium consisting of 
Eagle’s Minimal Essential Ingredient with Hank's salts, 
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L-glutamine, non-essential amino acids, 0.6 grams per 
liter vof bicarbonate, and 10 percent calf serum or fetal 
calf serum. Virus growth curves illustrate conditions of 
incubation yielding maximum yields. Studies of virus 
propagation determined that virus release into calf 
serum-free medium is accomplished by removing 
serum-containing medium before virus release occurs, 
thereby obtaining virus yields free of foreign serum 
protein and hence removing extraneous antigenic mate 
rial from the vaccine. 
Infectious virus yields from cultures so prepared av 
erage 6.0 to 7.0 X 106 plaque forming units per milliliter 
of cell free virion‘s. 
The virus suspensions harvested from such cell cul 
tures are centrifuged to remove extraneous cell debris 
and the supernatant solutions are pooled to constitute a 
production lot. The virus is chemically inactivated, the 
residual inactivating chemical is neutralized and the 
virus is tested for inactivation by the test described 
above. The inactivated virus pool is then concentrated 
to increase antigenic potency by ultra?ltration using a 
membrane with an exclusion limit of molecular weight 
5000. A sample of the concentrated vaccine is pelleted 
by centrifugation and the virus pellet is examined by 
thin layer electron microscopy to determine the pres 
ence of enveloped virions. The vaccine virus is tested 
for bacterial contamination. A stabilizer and a preserva 
tive such as thiomerosal are added. 
The inactivated vaccine virus is emulsi?ed with an 
equal amount of oil based adjuvant and dispensed asep 
tically into suitable containers. 
The following example illustrates the invention but is 
not intended to limit it thereto: 
EXAMPLE I 
Of a group of 21 pregnant mares, 11 were vaccinated 
with adjuvanted, inactivated virus vaccine with a ham 
ster irnmunogenic potency of 1:1600. There was no 
untoward local or generalized reaction to injection of 
the vaccine. An immune response evident by post-vac 
cinal increase in antibody and by other parameters ap 
plicable to in-vitro measurement of such response was 
noted for each mare. Sixty days after vaccination the - 
vaccinated mares and the 10 unvaccinated mares were 
exposed to virulent rhinopneumonitis virus by the intra 
nasal route which is the natural route of transmission of 
the virus. Six of the unvaccinated mares aborted 
rhinopenumonitis virus infected fetuses, four delivered 
normal foals. All of the vaccinated mares delivered 
normal foals. 
The invention being thus described, it will be obvious 
that the same may be varied in many ways. Such varia 
tions are not to be regarded as a departure from the 
spirit and scope of the invention, and all such modi?ca 
tions are intended to be included within the scope of the 
following claims. 
What is claimed is: ~ 
1. A vaccination method against disease caused by 
equine rhinopneumonitis virus in horses which com 
prises (a) vaccinating young female horses at any age 
past the time they reach their sixth month of age and 
revaccinating them at appropriate intervals until the 
females reach breeding age and become pregnant and 
(b) vaccinating the pregnant mares during their preg 
nancy and during subsequent pregnancies with an adju 
vanted, inactivated vaccine prepared by: ' 
propagating a virulent, immunogenically typical 
equine rhinopneumonitis virus in a susceptible, 
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cloned, diploid equine cell line that contains no 
equine blood cell antigens, and causing the virus to 
be released into a serum-free medium; 
harvesting virus from the cell culture, inactivating 
the virus, neutralizing the inactivating agent, con 
centrating the virus and adding an oil based immu 
nological adjuvant thereto. 
2. The vaccination method in accordance with claim 
1, wherein said harvested material meets the following 
criteria for safety and potency: 
(a) the virus is shown to be inactivated and non-infec 
tive by its lack of ability to infect susceptible cell 
cultures, and 
(b) the vaccine is shown to be immunogenically po 
tent by protection of hamsters against one million 
hamster median lethal doses of hamster virulent 
rhinopneumonitis virus. 
3. The vaccination method in accordance with claim 
1, wherein the young horses are revaccinated about 3 
weeks after their ?rst vaccination and then at yearly 
intervals thereafter until they reach breeding age. 
4. The vaccination method in accordance with claim 
3, wherein the pregnant mares are vaccinated at the 
?fth, seventh and ninth months of pregnancy. 
5. The method of preparing a vaccine for parenteral 
vaccination of horses against disease caused by equine 
rhinopneumonitis virus which comprises: 
propagating a virulent, immunogenically typical 
equine rhinopneumonitis virus in a susceptible 
equine, cloned, physiologically homogeneous, dip 
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‘loid cell line and multiplying the virus to obtain 
high yields of infectious virions; 
harvesting the virus in a serum free medium; 
completely inactivating the virions, neutralizing the 
inactivating agent, concentrating the virions by a 
method that maintains structural integrity and in 
creases antigenic potency; and 
mixing the concentrated, inactivated virions with an 
oil based immunological adjuvant, 
said harvested and adjuvant mixed material meeting 
the following criteria for safety and potency; 
(a) the virus is shown to be inactivated and non-infec 
tive by its lack of ability to infect susceptible cell 
cultures, and 
(b) the vaccine is shown to be immunogenically po 
tent by protection of hamsters against one million 
hamster median lethal doses of hamster virulent 
rhinopneumonitis virus. 
6. A vaccine for protection of horses against equine 
rhinopneumonitis prepared by the method of claim 5. 
7. The method of protecting horses against equine 
rhinopneumonitis which comprises vaccinating said 
horses with a vaccine prepared by the method of claim 
5. 
8. The vaccination method in accordance with claim 
1, wherein said rhinopneumonitis virus is obtained from 
an infected fetus. 
9. The method of claim 5, wherein said rhinop 
neumonitis virus is obtained from an infected equine 
fetal lung. 
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